Braveheart Bio Q2 FY26 net loss widens to $15 million; R&D expenses rise to $11.1 million

• Braveheart Bio posted a Q2 net loss of $15 million, versus a $0.4 million loss a year earlier.
• Net loss attributable to common stockholders widened to $18.6 million, from $0.4 million; loss per share deepened to $2.51 from $0.14.
• R&D expenses climbed to $11.1 million from no R&D expense, due to BHB-1893 advancement and Phase 3 preparation.
• G&A expenses rose to $4.8 million from less than $0.1 million, on higher headcount and public-company readiness costs.
• Cash and cash equivalents were $122.8 million at June 30; $527.3 million as adjusted for the IPO, expected to fund operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Braveheart Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-060904), on September 08, 2026, and is solely responsible for the information contained therein.